TVTX (Travere Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by TVTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-19 | GARY A LYONS | Director | MIXED | — | — |
| 2026-06-22 | Jula Inrig | CHIEF MEDICAL OFFICER | G | — | — |
| 2026-06-16 | Timothy Coughlin | Director | MIXED | — | — |
| 2026-06-16 | Roy D. Baynes | Director | MIXED | — | — |
| 2026-05-21 | John A Orwin | Director | A | — | — |
| 2026-05-21 | GARY A LYONS | Director | A | — | — |
| 2026-05-21 | Brinkley Ruth Williams | Director | A | — | — |
| 2026-05-21 | Jeffrey A Meckler | Director | A | — | — |
| 2026-05-21 | Sandra Poole | Director | A | — | — |
| 2026-05-21 | Timothy Coughlin | Director | A | — | — |
| 2026-05-21 | Roy D. Baynes | Director | A | — | — |
| 2026-05-21 | Suzanne Louise Bruhn | Director | A | — | — |
| 2026-05-21 | Ron Squarer | Director | A | — | — |
| 2026-05-19 | Timothy Coughlin | Director | Sell | — | — |
| 2026-05-06 | Jeffrey A Meckler | Director | MIXED | — | — |
| 2026-05-06 | Peter Heerma | CHIEF COMMERCIAL OFFICER | MIXED | — | — |
| 2026-05-06 | Christopher R. Cline | CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2026-05-06 | Jula Inrig | CHIEF MEDICAL OFFICER | MIXED | — | — |
| 2026-05-06 | WILLIAM E. ROTE | Chief Research Officer | MIXED | — | — |
| 2026-05-06 | Eric M Dube | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2026-05-06 | ELIZABETH E REED | Chief Legal Officer and GC | MIXED | — | — |
| 2026-05-06 | Roy D. Baynes | Director | MIXED | — | — |
| 2026-05-04 | Roy D. Baynes | Director | MIXED | — | — |
| 2026-04-23 | WILLIAM E. ROTE | Chief Research Officer | Sell | — | — |
| 2026-04-16 | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | MIXED | — | — |
| 2026-04-16 | GARY A LYONS | Director | MIXED | — | — |
| 2026-04-16 | Roy D. Baynes | Director | MIXED | — | — |
| 2026-04-15 | Jula Inrig | CHIEF MEDICAL OFFICER | MIXED | — | — |
| 2026-04-15 | WILLIAM E. ROTE | Chief Research Officer | A | — | — |
| 2026-04-15 | Peter Heerma | CHIEF COMMERCIAL OFFICER | MIXED | — | — |
| 2026-04-15 | Eric M Dube | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2026-04-15 | ELIZABETH E REED | Chief Legal Officer and GC | MIXED | — | — |
| 2026-04-15 | Christopher R. Cline | CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2026-04-07 | Roy D. Baynes | Director | MIXED | — | — |
| 2026-04-02 | ELIZABETH E REED | Chief Legal Officer and GC | MIXED | — | — |
| 2026-04-02 | Eric M Dube | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2026-03-18 | ELIZABETH E REED | Chief Legal Officer and GC | MIXED | — | — |
| 2026-02-24 | Eric M Dube | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2026-02-19 | ELIZABETH E REED | Chief Legal Officer and GC | MIXED | — | — |
| 2026-02-05 | Jula Inrig | CHIEF MEDICAL OFFICER | Sell | — | — |
| 2026-02-05 | ELIZABETH E REED | Chief Legal Officer and GC | Sell | — | — |
| 2026-02-05 | Christopher R. Cline | CHIEF FINANCIAL OFFICER | Sell | — | — |
| 2026-02-03 | Jula Inrig | CHIEF MEDICAL OFFICER | MIXED | — | — |
| 2026-02-03 | ELIZABETH E REED | Chief Legal Officer and GC | MIXED | — | — |
| 2026-02-03 | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | MIXED | — | — |
| 2026-02-03 | Christopher R. Cline | CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2026-02-03 | Peter Heerma | CHIEF COMMERCIAL OFFICER | MIXED | — | — |
| 2026-02-03 | WILLIAM E. ROTE | Chief Research Officer | MIXED | — | — |
| 2026-02-03 | Eric M Dube | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2026-01-27 | Eric M Dube | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | CHIEF EXECUTIVE OFFICER | 432,886 | — |
| — | Director | 166,419 | — |
| — | CHIEF COMMERCIAL OFFICER | 140,684 | — |
| — | CHIEF FINANCIAL OFFICER | 118,968 | — |
| — | Chief Research Officer | 118,237 | — |
| — | CHIEF MEDICAL OFFICER | 112,770 | — |
| — | Chief Legal Officer and GC | 105,211 | — |
| — | Director | 91,500 | — |
| — | Director | 66,250 | — |
| — | SVP, CHIEF ACCOUNTING OFFICER | 64,330 | — |
| — | Director | 62,400 | — |
| — | Chief Medical Officer | 49,021 | — |
| — | Director | 41,500 | — |
| — | Director | 39,375 | — |
| — | Director | 39,375 | — |
| — | Chief Financial Officer | 35,655 | — |
| — | Director | 34,000 | — |
| — | Director | 32,750 | — |
| — | Director | 29,750 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TVTX quote page; the site-wide leaderboard is on the insider transactions hub.